We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific's Positive Trial Results to Boost EP Unit
Read MoreHide Full Article
Boston Scientific Corporation (BSX - Free Report) recently presented favorable real-world data from the TRUE-HD study at the annual congress of the European Heart Rhythm Association (EHRA). This latest move is in line with the company’s strategy to gain traction in the global Electrophysiology (EP) market, which is poised to reach a value of around $4.73 billion by 2019 (as per data by Markets and Markets).
Study Results in Detail
The observational, prospective, non-randomized study — TRUE-HD study — covered 572 patients suitable for cardiac mapping and ablation for treating arrhythmia. However, the patients diagnosed with de novo atrial fibrillation were not enrolled under the study.
Notably, the TRUE-HD study evaluated the procedural process, acute success and safety for the mapping and ablation of various clinical arrhythmias.
Per the company, the study results displayed the safety and efficacy of RHYTHMIA Mapping System when used with INTELLAMAP ORION Mapping Catheter for mapping and supporting the treatment of different types of arrhythmias. Also, it included the cases where ablation of atrial fibrillation based on other techniques was a failure. RHYTHMIA Mapping Systemis a catheter-based, 3D cardiac mapping and navigation solution for helping in diagnosing and treating different types of arrhythmias.
A Glimpse of the EP Business
Boston Scientific’s EP business develops less-invasive medical technologies to diagnose and treat disorders of heart rate and rhythm.
Revenues at this division in fourth-quarter 2017 improved 20.7% year over year to $77 million (up 17.7% at CER). The upside was driven by higher uptake of the new RHYTHMIA HDx platform. Management continues to roll out the HDx platform in Europe and recently launched it in the United States as well as Japan.
Overall, the company continues to expand the toolkit that supports RHYTHMIA HDx, providing ablation technologies that match the excellence of its Mapping System. Additionally, it focuses on adding tools that expand the reach and utility of RHYTHMIA HDx in different procedures. In this regard, Boston Scientific expects the full-fledged commercialization of DirectSense technology in Europe and the United States in 2018 followed by a successful initial launch in Europe.
Moreover, in order to expand its EP business, Boston Scientific acquired Apama Medical Inc in October 2017. The company also intends to integrate its RHYTHMIA HDx Mapping System with Apama RF balloon system to improve the visualization of the heart during ablation processes.
Market Potential
Boston Scientific’s strategy to boost the EP business seems to be aligned with data provided by Allied Market Research. Per the report, the global Cardiac Monitoring and Cardiac Rhythm Management market is expected to see a CAGR of 7.6% from 2016 to 2022 to reach a value of $32,216 million.
We believe that unhealthy lifestyle and a rise in aging population should continue to result in high incidence of cardiovascular diseases. This is further supported by data provided by GBI Research. Per the report, the global cardiovascular disease market is anticipated to witness a CAGR of 4.1% by 2019, and within this space, the U.S. market is expected to witness the highest momentum at a CAGR of 4.7%.
Share Price Performance
Boston Scientific has been gaining investor confidence on consistently positive results. Last month, shares of the company have outperformed its broader industry. The stock has rallied 10.2% compared with the industry’s 3.8% gain.
Zacks Rank & Key Picks
Boston Scientific carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical sector are Bio-Rad Laboratories (BIO - Free Report) , athenahealth, Inc. and Varian Medical Systems, Inc. .
athenahealth is a Zacks #1 Ranked player. The company has a long-term expected earnings growth rate of 21.5%.
Varian Medical has a long-term expected earnings growth rate of 8%. The stock carries a Zacks Rank #2 (Buy).
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Boston Scientific's Positive Trial Results to Boost EP Unit
Boston Scientific Corporation (BSX - Free Report) recently presented favorable real-world data from the TRUE-HD study at the annual congress of the European Heart Rhythm Association (EHRA). This latest move is in line with the company’s strategy to gain traction in the global Electrophysiology (EP) market, which is poised to reach a value of around $4.73 billion by 2019 (as per data by Markets and Markets).
Study Results in Detail
The observational, prospective, non-randomized study — TRUE-HD study — covered 572 patients suitable for cardiac mapping and ablation for treating arrhythmia. However, the patients diagnosed with de novo atrial fibrillation were not enrolled under the study.
Notably, the TRUE-HD study evaluated the procedural process, acute success and safety for the mapping and ablation of various clinical arrhythmias.
Per the company, the study results displayed the safety and efficacy of RHYTHMIA Mapping System when used with INTELLAMAP ORION Mapping Catheter for mapping and supporting the treatment of different types of arrhythmias. Also, it included the cases where ablation of atrial fibrillation based on other techniques was a failure. RHYTHMIA Mapping Systemis a catheter-based, 3D cardiac mapping and navigation solution for helping in diagnosing and treating different types of arrhythmias.
A Glimpse of the EP Business
Boston Scientific’s EP business develops less-invasive medical technologies to diagnose and treat disorders of heart rate and rhythm.
Revenues at this division in fourth-quarter 2017 improved 20.7% year over year to $77 million (up 17.7% at CER). The upside was driven by higher uptake of the new RHYTHMIA HDx platform. Management continues to roll out the HDx platform in Europe and recently launched it in the United States as well as Japan.
Overall, the company continues to expand the toolkit that supports RHYTHMIA HDx, providing ablation technologies that match the excellence of its Mapping System. Additionally, it focuses on adding tools that expand the reach and utility of RHYTHMIA HDx in different procedures. In this regard, Boston Scientific expects the full-fledged commercialization of DirectSense technology in Europe and the United States in 2018 followed by a successful initial launch in Europe.
Moreover, in order to expand its EP business, Boston Scientific acquired Apama Medical Inc in October 2017. The company also intends to integrate its RHYTHMIA HDx Mapping System with Apama RF balloon system to improve the visualization of the heart during ablation processes.
Market Potential
Boston Scientific’s strategy to boost the EP business seems to be aligned with data provided by Allied Market Research. Per the report, the global Cardiac Monitoring and Cardiac Rhythm Management market is expected to see a CAGR of 7.6% from 2016 to 2022 to reach a value of $32,216 million.
We believe that unhealthy lifestyle and a rise in aging population should continue to result in high incidence of cardiovascular diseases. This is further supported by data provided by GBI Research. Per the report, the global cardiovascular disease market is anticipated to witness a CAGR of 4.1% by 2019, and within this space, the U.S. market is expected to witness the highest momentum at a CAGR of 4.7%.
Share Price Performance
Boston Scientific has been gaining investor confidence on consistently positive results. Last month, shares of the company have outperformed its broader industry. The stock has rallied 10.2% compared with the industry’s 3.8% gain.
Zacks Rank & Key Picks
Boston Scientific carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical sector are Bio-Rad Laboratories (BIO - Free Report) , athenahealth, Inc. and Varian Medical Systems, Inc. .
Bio-Rad Laboratories sports a Zacks Rank #1(Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. The company has a long-term expected earnings growth rate of 20%.
athenahealth is a Zacks #1 Ranked player. The company has a long-term expected earnings growth rate of 21.5%.
Varian Medical has a long-term expected earnings growth rate of 8%. The stock carries a Zacks Rank #2 (Buy).
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>